FANCA and acute promyelocytic leukemia: To further validate that loss of FANCA sensitizes AML cells to low concentration of volasertib, we stably knocked down FANCA using shRNA in four different AML cell lines: THP-1 (acute monocytic leukemia), HL60 (acute promyelocytic leukemia), Kasumi-1 (acute myeloblastic leukemia), and OCI-AML-5 (Fig. 2B–E).